-
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
WorldPharmaNews
December 21, 2021
Novartis announced the introduction of T-Charge™, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline.
-
Quell raises $156m Series B funds to develop cell therapies
Pharmaceutical-Business-Review
November 30, 2021
Quell Therapeutics has raised $156m funding through an oversubscribed Series B funding round to advance its multi-modular engineered T regulatory (Treg) cell therapy pipeline and platform.
-
Link Health to obtain global rights for Bone Therapeutics’ cell therapy
Pharmaceutical-Technology
November 30, 2021
Link Health Pharma has entered a non-binding term sheet to acquire worldwide rights for Bone Therapeutics’ allogeneic bone cell therapy, ALLOB.
-
Lykan Bioscience Bolsters Cell Therapy Capabilities
ContractPharma
November 11, 2021
Lykan Bioscience, a contract development and manufacturing organization (CDMO) focused on cell-based therapies, has unveiled plans to expand its state-of-the-art, purpose-built facility in Hopkinton...
-
PBS Biotech secures $10 million to expand cell therapy manufacturing equipment portfolio
cphi-online
August 19, 2021
The capital will be used to expand and industrialise the company's range of single-use bioreactor systems and contract process development services
-
Astellas and Minovia Therapeutics to Collaborate on New Mitochondrial Cell Therapies
americanpharmaceuticalreview
August 02, 2021
Minovia Therapeutics, Ltd. and Astellas Pharma Inc. announced a worldwide strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction.
-
BioNTech to Acquire Kite’s TCR Cell Therapy Platform and Mfg. Facility
contractpharma
July 20, 2021
BioNTech SE and Kite, a Gilead Company, have entered a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD.
-
Senti Bio Invests in Cell Therapy Manufacturing Facility
contractpharma
June 24, 2021
92,000 square-foot cGMP facility will be designed to support clinical and commercial-scale production of allogeneic CAR-NK cell pipeline.
-
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
firstwordpharma
June 23, 2021
Century Therapeutics (NASDAQ: IPSC) today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share
-
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
prnewswire
June 23, 2021
We are in a new era of medicine where groundbreaking biopharmaceutical research and development is transforming medicine, but these innovations are meaningless if they don't reach patients, including those in underserved communities.